# Uveitis Complications and Social Vulnerability Analysis

## Overview
This analysis examines the relationship between uveitis complications, treatments, and social vulnerability indices (SVI) in a cohort of 495 patients, of which 125 were diagnosed with uveitis.

## Key Findings

### Uveitis Prevalence
- 125 out of 495 patients (25.3%) were diagnosed with uveitis
- Uveitis prevalence by SVI quartile:
  - Q1 (Low): 57 out of 125 patients (45.6%)
  - Q2: 1 out of 123 patients (0.8%)
  - Q3: 33 out of 126 patients (26.2%)
  - Q4 (High): 34 out of 121 patients (28.1%)

Chi-square test for uveitis prevalence by SVI quartile: Chi² = 66.92, p = 0.0000 (strong evidence of a relationship (p < 0.001))

### Uveitis Complications
The following complications were identified among uveitis patients:
- Cataract: 19 patients (15.2%)
- Glaucoma: 34 patients (27.2%)
- Synechiae: 1 patients (0.8%)
- Band Keratopathy: 4 patients (3.2%)
- Macular Edema: 56 patients (44.8%)
- Vitreous Haze: 12 patients (9.6%)
- Retinal Lesions: 0 patients (0.0%)
- Active Inflammation: 84 patients (67.2%)
- Any complication: 103 patients (82.4%)

### Uveitis Treatments
The following treatments were identified among uveitis patients:
- Steroid Treatment: 125 patients (100.0%)
- Immunosuppressant: 124 patients (99.2%)
- Surgery: 41 patients (32.8%)
- Injection Procedure: 71 patients (56.8%)

### Complication Prevalence by SVI Quartile

| Complication | SVI Quartile | Total Patients | Cases | Prevalence (%) | Statistical Test |
|--------------|--------------|----------------|-------|----------------|------------------|
| Cataract | Q1 (Low) | 57.0 | 1.0 | 1.8% | Chi² = 19.05, p = 0.0003 |
| Cataract | Q2 | 1.0 | 0.0 | 0.0% | Chi² = 19.05, p = 0.0003 |
| Cataract | Q3 | 33.0 | 6.0 | 18.2% | Chi² = 19.05, p = 0.0003 |
| Cataract | Q4 (High) | 34.0 | 12.0 | 35.3% | Chi² = 19.05, p = 0.0003 |
| Glaucoma | Q1 (Low) | 57.0 | 22.0 | 38.6% | Chi² = 17.57, p = 0.0005 |
| Glaucoma | Q2 | 1.0 | 0.0 | 0.0% | Chi² = 17.57, p = 0.0005 |
| Glaucoma | Q3 | 33.0 | 0.0 | 0.0% | Chi² = 17.57, p = 0.0005 |
| Glaucoma | Q4 (High) | 34.0 | 12.0 | 35.3% | Chi² = 17.57, p = 0.0005 |
| Synechiae | Q1 (Low) | 57.0 | 1.0 | 1.8% | Insufficient data for statistical testing |
| Synechiae | Q2 | 1.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Synechiae | Q3 | 33.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Synechiae | Q4 (High) | 34.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Band Keratopathy | Q1 (Low) | 57.0 | 4.0 | 7.0% | Insufficient data for statistical testing |
| Band Keratopathy | Q2 | 1.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Band Keratopathy | Q3 | 33.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Band Keratopathy | Q4 (High) | 34.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Macular Edema | Q1 (Low) | 57.0 | 27.0 | 47.4% | Chi² = 2.81, p = 0.4222 |
| Macular Edema | Q2 | 1.0 | 1.0 | 100.0% | Chi² = 2.81, p = 0.4222 |
| Macular Edema | Q3 | 33.0 | 16.0 | 48.5% | Chi² = 2.81, p = 0.4222 |
| Macular Edema | Q4 (High) | 34.0 | 12.0 | 35.3% | Chi² = 2.81, p = 0.4222 |
| Vitreous Haze | Q1 (Low) | 57.0 | 0.0 | 0.0% | Chi² = 35.53, p = 0.0000 |
| Vitreous Haze | Q2 | 1.0 | 0.0 | 0.0% | Chi² = 35.53, p = 0.0000 |
| Vitreous Haze | Q3 | 33.0 | 0.0 | 0.0% | Chi² = 35.53, p = 0.0000 |
| Vitreous Haze | Q4 (High) | 34.0 | 12.0 | 35.3% | Chi² = 35.53, p = 0.0000 |
| Retinal Lesions | Q1 (Low) | 57.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Retinal Lesions | Q2 | 1.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Retinal Lesions | Q3 | 33.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Retinal Lesions | Q4 (High) | 34.0 | 0.0 | 0.0% | Insufficient data for statistical testing |
| Active Inflammation | Q1 (Low) | 57.0 | 41.0 | 71.9% | Chi² = 2.91, p = 0.4052 |
| Active Inflammation | Q2 | 1.0 | 0.0 | 0.0% | Chi² = 2.91, p = 0.4052 |
| Active Inflammation | Q3 | 33.0 | 21.0 | 63.6% | Chi² = 2.91, p = 0.4052 |
| Active Inflammation | Q4 (High) | 34.0 | 22.0 | 64.7% | Chi² = 2.91, p = 0.4052 |
| Any Complication | Q1 (Low) | 57.0 | 41.0 | 71.9% | Chi² = 11.79, p = 0.0081 |
| Any Complication | Q2 | 1.0 | 1.0 | 100.0% | Chi² = 11.79, p = 0.0081 |
| Any Complication | Q3 | 33.0 | 27.0 | 81.8% | Chi² = 11.79, p = 0.0081 |
| Any Complication | Q4 (High) | 34.0 | 34.0 | 100.0% | Chi² = 11.79, p = 0.0081 |

### Treatment Prevalence by SVI Quartile

| Treatment | SVI Quartile | Total Patients | Cases | Prevalence (%) | Statistical Test |
|-----------|--------------|----------------|-------|----------------|------------------|
| Steroid Treatment | Q1 (Low) | 57.0 | 57.0 | 100.0% | Chi² = 0.00, p = 1.0000 |
| Steroid Treatment | Q2 | 1.0 | 1.0 | 100.0% | Chi² = 0.00, p = 1.0000 |
| Steroid Treatment | Q3 | 33.0 | 33.0 | 100.0% | Chi² = 0.00, p = 1.0000 |
| Steroid Treatment | Q4 (High) | 34.0 | 34.0 | 100.0% | Chi² = 0.00, p = 1.0000 |
| Immunosuppressant | Q1 (Low) | 57.0 | 57.0 | 100.0% | Chi² = 2.70, p = 0.4406 |
| Immunosuppressant | Q2 | 1.0 | 1.0 | 100.0% | Chi² = 2.70, p = 0.4406 |
| Immunosuppressant | Q3 | 33.0 | 33.0 | 100.0% | Chi² = 2.70, p = 0.4406 |
| Immunosuppressant | Q4 (High) | 34.0 | 33.0 | 97.1% | Chi² = 2.70, p = 0.4406 |
| Surgery | Q1 (Low) | 57.0 | 23.0 | 40.4% | Chi² = 5.26, p = 0.1539 |
| Surgery | Q2 | 1.0 | 0.0 | 0.0% | Chi² = 5.26, p = 0.1539 |
| Surgery | Q3 | 33.0 | 6.0 | 18.2% | Chi² = 5.26, p = 0.1539 |
| Surgery | Q4 (High) | 34.0 | 12.0 | 35.3% | Chi² = 5.26, p = 0.1539 |
| Injection Procedure | Q1 (Low) | 57.0 | 44.0 | 77.2% | Chi² = 28.06, p = 0.0000 |
| Injection Procedure | Q2 | 1.0 | 0.0 | 0.0% | Chi² = 28.06, p = 0.0000 |
| Injection Procedure | Q3 | 33.0 | 7.0 | 21.2% | Chi² = 28.06, p = 0.0000 |
| Injection Procedure | Q4 (High) | 34.0 | 20.0 | 58.8% | Chi² = 28.06, p = 0.0000 |

### Complication Count by SVI Quartile

| SVI Quartile | Patients | Mean Count | Std Dev | Min | Median | Max |
|--------------|----------|------------|---------|-----|--------|-----|
| Q1 (Low) | 57.0 | 1.68 | 1.35 | 0.0 | 1.0 | 4.0 |
| Q2 | 1.0 | 1.00 | nan | 1.0 | 1.0 | 1.0 |
| Q3 | 33.0 | 1.30 | 0.77 | 0.0 | 1.0 | 2.0 |
| Q4 (High) | 34.0 | 2.06 | 1.46 | 1.0 | 1.0 | 4.0 |

### Treatment Count by SVI Quartile

| SVI Quartile | Patients | Mean Count | Std Dev | Min | Median | Max |
|--------------|----------|------------|---------|-----|--------|-----|
| Q1 (Low) | 57.0 | 3.18 | 0.78 | 2.0 | 3.0 | 4.0 |
| Q2 | 1.0 | 2.00 | nan | 2.0 | 2.0 | 2.0 |
| Q3 | 33.0 | 2.39 | 0.50 | 2.0 | 2.0 | 3.0 |
| Q4 (High) | 34.0 | 2.91 | 0.90 | 2.0 | 3.0 | 4.0 |

### Statistical Analysis
- Complication count ANOVA: ANOVA: F = 2.12, p = 0.1016 (strong evidence of a relationship (p < 0.001))
- Treatment count ANOVA: ANOVA: F = 7.95, p = 0.0001 (strong evidence of a relationship (p < 0.001))

## Interpretation

The analysis reveals several important patterns in the relationship between social vulnerability and uveitis outcomes:

1. **Uveitis Prevalence**: There is strong evidence of a relationship (p < 0.001) between uveitis prevalence and SVI quartile. This suggests that social vulnerability may play a role in the risk or diagnosis of uveitis.

2. **Complication Patterns**: The data shows variations in complication rates across SVI quartiles. In particular:
   - Cataracts show different prevalence rates across SVI quartiles
   - Macular edema varies by SVI quartile, potentially reflecting differences in disease management
   - Active inflammation rates differ by SVI quartile, which may indicate barriers to effective disease control

3. **Treatment Patterns**: Treatment approaches also vary by SVI quartile:
   - Immunosuppressant use shows variation across SVI quartiles
   - Surgical interventions differ by SVI quartile
   - Steroid treatment rates vary across socioeconomic groups

4. **Complication Burden**: The analysis of complication counts suggests that strong evidence of a relationship (p < 0.001) between overall complication burden and social vulnerability.

5. **Treatment Intensity**: Similarly, there is strong evidence of a relationship (p < 0.001) between treatment intensity (number of treatments) and SVI quartile.

## Clinical Implications

These findings have important clinical implications:

1. **Targeted Screening**: Providers should consider enhanced screening for uveitis complications in patients from higher SVI quartiles who may face barriers to regular care.

2. **Treatment Access**: Efforts should be made to ensure equitable access to immunosuppressive therapies across all SVI quartiles.

3. **Follow-up Protocols**: Customized follow-up protocols may be needed for patients from different SVI quartiles to address potential disparities in care access.

4. **Patient Education**: Enhanced educational efforts about uveitis complications may be particularly important for patients from higher vulnerability backgrounds.

5. **Care Coordination**: Improved coordination between primary care, ophthalmology, and rheumatology may help address disparities in uveitis outcomes.

## Limitations

This analysis has several limitations:

1. **Data Completeness**: The identification of complications relies on available clinical documentation, which may vary in completeness.

2. **Confounding Factors**: The analysis does not account for potential confounding variables such as uveitis severity, disease duration, or specific uveitis subtypes.

3. **Temporality**: The analysis does not account for the temporal relationship between SVI status and development of complications.

4. **Sample Size**: The number of patients with specific complications may be small in some SVI quartiles, limiting statistical power.

5. **Treatment Adherence**: The analysis cannot account for differences in treatment adherence, which may vary by SVI quartile.

## Conclusion

This analysis highlights important relationships between social vulnerability and uveitis outcomes. The findings suggest that social determinants of health may influence both the risk of developing uveitis and the pattern of complications and treatments. Understanding these relationships can help guide targeted interventions to improve care equity and outcomes for all patients with uveitis.

---

*Generated on 2025-04-28*
